ADCs have moved from niche to mainstream commercial scaling, with the global market at ~USD 17.2 bn in 2025 and a forecast USD 66.2 bn by 2030 (30% CAGR). This piece breaks down why ADC manufacturing is hard, maps the capacity plays of six players (WuXi XDC / Lonza / Samsung / Piramal / Merck / Catalent), and shows how M&A - Lonza's Exelead buy, Samsung's Rockville acquisition - is reshaping the high-potency and sterile capacity landscape.

Antibody-drug conjugates are consuming capacity at mainstream commercial speed. The global ADC drug market reached about USD 17.2 bn in 2025, with over 20 approved products posting USD 16.5-16.8 bn in combined sales - more than double the ~USD 5.5 bn of 2021; Enhertu alone did USD 4.982 bn (+32.7%), while Padcev and Polivy each crossed the USD 2 bn threshold. As commercial scale meets technical barriers, an arms race around conjugation tech, capacity positioning and M&A consolidation is already underway.

1. Market: from niche to mainstream, 30% CAGR

Frost & Sullivan forecasts the global ADC market growing from USD 10.4 bn in 2023 to USD 66.2 bn by 2030, a 30.3% CAGR, far above the 9.2% overall biologics rate. Technology iteration is extending the conjugation paradigm from traditional ADCs to XDCs, with diversified payload-carrier combinations opening wider space. Outsourcing penetration has jumped: the global ADC and broad bioconjugate CRDMO market expanded from USD 0.5 bn to USD 3.5 bn, heading to USD 11 bn by 2030. On a contract-manufacturing basis, Visiongain estimates USD 2.14 bn in 2026 rising to USD 6.31 bn by 2036 (11.4% CAGR); North America holds ~47% and APAC is the fastest-growing region - the upcycle propagates up the value chain, directly pulling CRDMO demand.

2. Why ADC manufacturing is hard: three products fused into one

An ADC is not a bigger antibody; it fuses three products into one - a monoclonal antibody, a highly potent cytotoxic payload, and a chemical linker that controls release - each governed by a different manufacturing discipline under a single quality system, with none of the tolerance a conventional biologic might allow. The first hard problem is linker-payload chemistry: modern payloads are not ordinary small molecules, requiring OEB-5 high-potency containment (occupational limits down to nanograms per cubic metre), kilogram-scale GMP payload reactors, DAR characterization and validated purification. The second is conjugation and sterile drug product: conjugation and purification account for ~40% of 2026 ADC process value and are the highest-value step; cytotoxic HPAPI payload synthesis is the fastest-growing sub-segment. Their combination makes ADC outsourcing rates naturally higher than for antibodies.

3. The competitive map: six players positioning

Table 1 Major ADC CDMO capacity and moves in 2026 (cxdmo.com)
PlayerPositioningADC capacity / moveSignal
WuXi XDCPure-play ADC specialistSingapore Tuas ~25-30k m2, GMP early 2026; BCM3 up to 2000 L/batch; DP4 >8 m vials/yr; OEB-5 payload-linker labService orders +50%; record 51 new signed projects
LonzaIntegrated giantVisp payload-linker/HPAPI expansion 2028; Stein commercial ADC aseptic line 2030Acquired Exelead (ex-Merck ADC/HPAPI)
Samsung BiologicsScale challengerSongdo dedicated ADC facility (500 L conjugation); formulation by 2027; Rockville GSK 60 kL (early 2026)Bio Campus III names ADC a primary modality
PiramalHigh-potency specialistGrangemouth completed 1,500th ADC batch (Mar 2026, commercial oncology)Outsourced ADC extends to recurring commercial mfg
Merck KGaAPayload-linker sourceExelead acquired by LonzaHigh-potency & sterile assets folded in
Catalent (Novo Holdings)Aseptic fill-finishBiologics aseptic fill-finish & drug-device combosCritical commercial DP link
Capacity definitions span drug substance, conjugation and fill-finish and are not directly comparable; data from company disclosures and industry reporting (mid-2026).

4. The M&A reshuffle: ADC pushes CDMO M&A toward high-potency and sterile

The ADC upcycle is rewriting CDMO M&A logic - buyers are not chasing generic antibody tanks but scarce high-potency containment and sterile DP assets. Lonza bolstered linker-payload capability by acquiring Exelead (Merck's former ADC/HPAPI asset) and is expanding Visp while adding a Stein commercial ADC aseptic line. Samsung Biologics paid USD 353 m for GSK's Rockville facility (~60 kL, its first US base), folding ADC and biologic drug substance together. Buying ready-made high-potency + sterile capacity bypasses the long lead time of greenfield construction and gives global clients scale immediately - the core motive of the 2026 acquisition wave.

5. The China player: WuXi XDC's pure-play edge and the dual-source cure

In this three-way fight, WuXi XDC is the purest ADC specialist. Its Singapore Tuas site (~25-30k m2) is designed as an end-to-end bioconjugate center: a dual-function line producing both mAb intermediates and conjugate drug substance at up to 2,000 L per batch, a conjugation DP line with >8 m vials/year, and an OEB-5 payload-linker lab with kilogram-scale GMP payload reactors. But it carries a strategic baggage its rivals do not: its Chinese parentage keeps it under the long shadow of US legislative scrutiny of Chinese CDMOs - which is precisely why 'dual-source supply + a Singapore address' is its most important pitch. In 2026 WuXi XDC signed a record 51 new integrated projects and grew service orders 50%, showing that under policy noise clients want not 'de-China' but 'one more compliant, substitutable address'.

6. Outlook: too much capacity?

APAC's heavy build-out raises 'are they building too much' questions, but the answer hinges on capacity specificity. ADC-specific conjugation facilities are small-footprint, high-barrier dedicated assets, not comparable to hundreds-of-thousands-of-litres antibody tanks; what is truly scarce is commercially validated conjugation and sterile capability - Piramal's 1,500th commercial oncology ADC batch is the footnote proving the moat. In short, the oversupply risk sits in generic antibody capacity, not in ADC-specific conjugation. The next phase pits CDMOs not on 'do you have tanks' but on 'can you stably synthesize one drug from antibody, payload and linker under high-potency containment'.

An ADC is not a bigger antibody. It fuses three products into one - antibody, potent toxin, linker - each under a different manufacturing discipline within one quality system, with none of the variability tolerance a conventional biologic might permit.

cxdmo.com Insight

FAQ

How big and how fast is the ADC CDMO market?

Frost & Sullivan: global ADC drug market USD 10.4 bn (2023) → USD 66.2 bn (2030), 30.3% CAGR; broad ADC/XDC CRDMO USD 0.5 bn → USD 3.5 bn → USD 11 bn (2030). Contract-manufacturing basis Visiongain estimates USD 2.14 bn (2026) → USD 6.31 bn (2036), 11.4% CAGR. Scopes differ, but all agree on growth well above biologics overall.

Why is ADC outsourcing rate naturally higher than for antibodies?

Because manufacturing difficulty rises exponentially: an ADC combines antibody, cytotoxic payload and linker, requiring high-potency containment (OEB-5), kilogram-scale GMP payload synthesis, DAR characterization, validated purification and sterile DP that most sponsors cannot build in-house. Conjugation and purification are ~40% of process value and HPAPI synthesis is the fastest-growing sub-segment - the barrier directly lifts outsourcing and pricing.

What differentiates WuXi XDC from Lonza / Samsung?

It is a pure-play ADC specialist with the most focused end-to-end capability; its Singapore Tuas site pairs an OEB-5 payload-linker lab with 8 m vials/year DP capacity. Under policy shadow, 'dual-source + Singapore address' is its core hedge against geopolitics. Record 51 new signed projects and +50% service orders in 2026 show clients want a compliant substitutable address, not pure de-China.

Will ADC capacity be oversupplied?

The risk concentrates in generic antibody drug substance, not in ADC-specific conjugation. ADC conjugation facilities are small-footprint, high-barrier dedicated assets; what is scarce is commercially validated conjugation and sterile capability (e.g. Piramal's 1,500th commercial ADC batch). Near-term, dedicated conjugation capacity remains tight.

This article is compiled from public reporting. Original source: Compiled from Frost & Sullivan, Visiongain, Persistence Market Research, Phirda, BioPharma APAC, and WuXi XDC / Lonza / Samsung Biologics public disclosures · For industry reference only; not investment advice.